Geoffrey Porges
Stock Analyst at SVB Leerink
(1.35)
# 3,604
Out of 5,081 analysts
121
Total ratings
43.37%
Success rate
-6.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geoffrey Porges
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Market Perform | $52 → $56 | $25.73 | +117.64% | 10 | Dec 15, 2021 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $68 → $100 | $25.74 | +288.50% | 8 | Nov 18, 2021 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $798 → $850 | $735.00 | +15.65% | 16 | Nov 5, 2021 | |
| HALO Halozyme Therapeutics | Maintains: Outperform | $50 → $48 | $66.00 | -27.27% | 2 | Nov 3, 2021 | |
| AMGN Amgen | Maintains: Market Perform | $234 → $216 | $341.36 | -36.72% | 12 | Nov 3, 2021 | |
| ABBV AbbVie | Maintains: Outperform | $142 → $135 | $226.46 | -40.39% | 16 | Nov 1, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | $11 | $20.22 | -45.60% | 1 | Nov 1, 2021 | |
| GILD Gilead Sciences | Maintains: Outperform | $77 → $75 | $124.68 | -39.85% | 14 | Oct 29, 2021 | |
| SNY Sanofi | Upgrades: Outperform | n/a | $49.75 | - | 2 | Sep 27, 2021 | |
| TBPH Theravance Biopharma | Maintains: Outperform | $29 → $10 | $18.90 | -47.08% | 9 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $875 → $750 | $8.11 | +9,147.84% | 8 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $170 → $175 | $452.11 | -61.29% | 9 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $96 → $84 | $33.99 | +147.13% | 3 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $49.17 | - | 1 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61 | $7.08 | +761.58% | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $181.80 | - | 8 | Mar 16, 2017 |
Pfizer
Dec 15, 2021
Maintains: Market Perform
Price Target: $52 → $56
Current: $25.73
Upside: +117.64%
Arcus Biosciences
Nov 18, 2021
Maintains: Outperform
Price Target: $68 → $100
Current: $25.74
Upside: +288.50%
Regeneron Pharmaceuticals
Nov 5, 2021
Maintains: Outperform
Price Target: $798 → $850
Current: $735.00
Upside: +15.65%
Halozyme Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $50 → $48
Current: $66.00
Upside: -27.27%
Amgen
Nov 3, 2021
Maintains: Market Perform
Price Target: $234 → $216
Current: $341.36
Upside: -36.72%
AbbVie
Nov 1, 2021
Maintains: Outperform
Price Target: $142 → $135
Current: $226.46
Upside: -40.39%
Roivant Sciences
Nov 1, 2021
Initiates: Outperform
Price Target: $11
Current: $20.22
Upside: -45.60%
Gilead Sciences
Oct 29, 2021
Maintains: Outperform
Price Target: $77 → $75
Current: $124.68
Upside: -39.85%
Sanofi
Sep 27, 2021
Upgrades: Outperform
Price Target: n/a
Current: $49.75
Upside: -
Theravance Biopharma
Sep 16, 2021
Maintains: Outperform
Price Target: $29 → $10
Current: $18.90
Upside: -47.08%
Aug 10, 2021
Maintains: Outperform
Price Target: $875 → $750
Current: $8.11
Upside: +9,147.84%
Jul 30, 2021
Maintains: Underperform
Price Target: $170 → $175
Current: $452.11
Upside: -61.29%
May 10, 2021
Maintains: Market Perform
Price Target: $96 → $84
Current: $33.99
Upside: +147.13%
Mar 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $49.17
Upside: -
Nov 28, 2018
Initiates: Outperform
Price Target: $61
Current: $7.08
Upside: +761.58%
Mar 16, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $181.80
Upside: -